Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 440 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Asciminib April 3, 2026 Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated... November 9, 2022 Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with... February 17, 2026 EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... October 5, 2021 Load more HOT NEWS Scientists developing urine and blood tests to detect brain tumours How to Safely Keep Up With Your Cancer Screening and Care... Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment... Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of...
